相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia
Steven R. Schuster et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Current status of stem cell mobilization
Morie A. Gertz
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Irene M. Ghobrial et al.
CLINICAL CANCER RESEARCH (2010)
Prevalence, Clinical Aspects, and Natural History of IgM MGUS
Mary L. McMaster et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2010)
Prognostic Factors in Follicular Lymphoma
Thomas Relander et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy
D. A. Carney et al.
LEUKEMIA (2010)
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia
Stefan Peinert et al.
LEUKEMIA & LYMPHOMA (2010)
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)
Efstathios Kastritis et al.
LEUKEMIA RESEARCH (2010)
Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines
Stephen M. Ansell et al.
MAYO CLINIC PROCEEDINGS (2010)
Novel treatment regimens for Waldenstrom's macroglobulinemia
Ramon Garcia-Sanz et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial
Morie A. Gertz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide and Rituximab in Waidenstrom's Macroglobulinemia
Steven P. Treon et al.
CLINICAL CANCER RESEARCH (2009)
Monoclonal gammopathy and neuropathy
Sindhu Ramchandren et al.
CURRENT OPINION IN NEUROLOGY (2009)
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs
Xavier Leleu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C. Buske et al.
LEUKEMIA (2009)
Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification
Jason R. Westin et al.
Current Hematologic Malignancy Reports (2009)
Bortezomib in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Christine Chen et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Prognostication in Young and Old Patients with Waldenstrom's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase
Efstathios Kastritis et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia
Leukothea Ioakimidis et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Waldenstrom's Macroglobulinemia
Sigbjorn Berentsen
CLINICAL LYMPHOMA & MYELOMA (2009)
Fludarabine-Based Combination Therapies for Waldenstrom's Macroglobulinemia
Alessandra Tedeschi et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Prognostic Relevance of 6q Deletion in Waldenstrom's Macroglobulinemia: A Multicenter Study
Hong Chang et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenstrom's Macroglobulinemia
Robert A. Kyle et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Waldenstrom's Macroglobulinemia: Hyperviscosity Syndrome and Cryoglobulinemia
Marvin J. Stone
CLINICAL LYMPHOMA & MYELOMA (2009)
Thalidomide and rituximab in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2008)
Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia
Umberto Vitolo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens
Meletios Athanasios Dimopoulos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Pathogenesis and progression of monoclonal gammopathy of undetermined significance
J. Blade et al.
LEUKEMIA (2008)
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu et al.
LEUKEMIA & LYMPHOMA (2008)
The incidence and survival of Waldenstrom's Macroglobulinaernia in South East England
K. J. Phekoo et al.
LEUKEMIA RESEARCH (2008)
Neurological manifestations of Waldenstrom macroglobulinemia
Joachim M. Baehring et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome
William Blum et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
IM Ghobrial et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
Constantine S. Tam et al.
CANCER (2006)
Autoantibody activity in Waldenstrom's macroglobulinemia
MJ Stone et al.
CLINICAL LYMPHOMA (2005)
Waldenstrom's macroglobulinemia
MA Dimopoulos et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98)
MA Gertz et al.
LEUKEMIA & LYMPHOMA (2004)
Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response
IM Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Initial immunoglobulin M 'Flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia an eastern cooperative oncology group study
IM Ghobrial et al.
CANCER (2004)
Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia:: a single center study of 22 cases
H Chang et al.
LEUKEMIA (2004)
Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia:: A two-institution study
M Björkholm et al.
SEMINARS IN ONCOLOGY (2003)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)
MV Dhodapkar et al.
SEMINARS IN ONCOLOGY (2003)
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil
RA Kyle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
